



Art.4(1)(b)

Art.4(1)(b)

Mr Valdis Dombrovskis
Executive Vice-President
European Commission

Paris, 23 May 2022

Dear Executive Vice-President Dombrovskis,

As a globally operating pharmaceutical company, Sanofi is assessing the longer-term implications of the war in Ukraine and the fall-out from the pandemic, in terms of health, trade and economic policies. Given the considerable challenges Europe faces, we strongly believe a strategic sector such as ours must play its part in Europe's recovery efforts and its ambition of global technological leadership in key sectors.

On 27 June, I will be in Brussels and would greatly welcome the opportunity for a meeting with you.

I would like to exchange with you on three main topics related to US, China and Europe:

- On the importance of building further on the EU-US Trade and Technology Council to identify areas that could become part of a joint innovation agenda in biopharmaceuticals between the EU and the US,
- On the need to continue driving regulatory convergence with key regions, in particular China and the establishment of an EU-China exchange on biopharmaceutical innovation,
- On the recovery efforts throughout Europe and the need for reforming and investing in sustainable and efficient healthcare systems.

We are a leading EU-headquartered pharmaceutical company with significant investment in R&D and manufacturing in Europe, with three R&D hubs in Belgium, France and Germany and almost 40 production sites in Europe. We would be delighted to welcome you to one of our sites, for example in Belgium, to show the significant industrial transformation Sanofi is investing in.

As we approach the half century mark of the company's existence, we have taken on the most important transformation and modernization challenge in our history. We are driven by the clear ambition to do innovative science to develop breakthrough medicines and vaccines and get them to the people who need them. We are raising our commitments to society, putting environmental sustainability and affordable access at the centre of our vision for the future.

I very much hope that an exchange with you on these topics is possible.

Yours sincerely,

Art.4(1)(b)

Art.4(1)(b)

Art.4(1)(b)

From: Art.4(1)(b) (CAB-DOMBROVSKIS)
Sent: Monday, June 13, 2022 10:31 AM
To: Art.4(1)(b)@sanofi.com; Art.4(1)(b)@sanofi.com>
Cc: Art.4(1)(b) (CAB-DOMBROVSKIS) Art.4(1)(b) @ec.europa.eu;
Art.4(1)(b) (CAB-DOMBROVSKIS) Art.4(1)(b) @ec.europa.eu>
Subject: Ares(2022)3891558: FW: Meeting enquiry – Sanofi CEO
Importance: High

Dear Art.4(1)(b),

Thank you very much for your kind letter and the request for a meeting with Mr Dombrovskis on 27 June in Brussels.

I regret to inform you that due to previously confirmed calendar commitments, Mr Dombrovskis will, unfortunately, be unavailable for a personal meeting.

We apologise for being unable to accommodate your request this time.

Yours sincerely,

Art.4(1)(b)

Art.4(1)(b)



Art.4(1)(b) Žaneta VEGNERE, Deputy Head of Cabinet
Cabinet of Executive Vice-President Valdis Dombrovskis
+32 2 29 Art.4(1)(b)
Art.4(1)(b) @ec.europa.eu